MercorBiotech Investment Analyst — Drug Asset & Company Assessment
Good fit for: scientists, researchers, and PhD holders in STEM fields.
Listing verified on the platform’s official board. Last checked November 11, 2026.
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
- Create and critique rubrics that analyze commercial drugs and drug-development programs
- Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
- Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
- Apply your assessment across the pilot's set of companies (~5–10)
Requirements
- US-based biotech / healthcare investment analyst with a specialist-fund background
- Familiarity with biotech/pharma development programs
- Able to assess a drug asset and the company behind it end-to-end
- 5+ years evaluating biotech/pharma companies or assets
Engagement Details
- Duration: Approximately 10–20 hours over a 1–2 week pilot
- Remote — US-based
Why Participate
- Help improve expert AI evaluation of drugs and drug-development programs
- Recurring engagement for strong contributors
Applying via Mercor: Mercor pays twice a week once you are hired and billing work. Sign-up is free; expect a resume upload and an AI interview before matching.